177 related articles for article (PubMed ID: 37903949)
21. Discovery of New VEGFR-2 Inhibitors: Design, Synthesis, Anti-Proliferative Evaluation, Docking, and MD Simulation Studies.
Elkaeed EB; Yousef RG; Khalifa MM; Ibrahim A; Mehany ABM; Gobaara IMM; Alsfouk BA; Eldehna WM; Metwaly AM; Eissa IH; El-Zahabi MA
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234734
[TBL] [Abstract][Full Text] [Related]
22. Biphenylurea/thiourea derivatives tagged with heteroarylsulfonamide motifs as novel VEGFR2 inhibitors; Design, synthesis and anti-angiogenic activity.
Al-Ansary GH; Nasr T; Taha H; Fayad W; Mahgoub S
Bioorg Chem; 2021 Feb; 107():104640. PubMed ID: 33485105
[TBL] [Abstract][Full Text] [Related]
23. Design and discovery of thioether and nicotinamide containing sorafenib analogues as multikinase inhibitors targeting B-Raf, B-Raf
Sun S; He Z; Huang M; Wang N; He Z; Kong X; Yao J
Bioorg Med Chem; 2018 May; 26(9):2381-2391. PubMed ID: 29631788
[TBL] [Abstract][Full Text] [Related]
24. Design and synthesis of new 2-oxoquinoxalinyl-1,2,4-triazoles as antitumor VEGFR-2 inhibitors.
Zengin M; Unsal Tan O; Arafa RK; Balkan A
Bioorg Chem; 2022 Apr; 121():105696. PubMed ID: 35217379
[TBL] [Abstract][Full Text] [Related]
25. Novel 4-(piperazin-1-yl)quinolin-2(1H)-one bearing thiazoles with antiproliferative activity through VEGFR-2-TK inhibition.
Hassan A; Badr M; Hassan HA; Abdelhamid D; Abuo-Rahma GEA
Bioorg Med Chem; 2021 Jun; 40():116168. PubMed ID: 33962153
[TBL] [Abstract][Full Text] [Related]
26. Synthesis of novel nicotinic acid derivatives of potential antioxidant and anticancer activity.
El-Dash Y; Khalil NA; Ahmed EM; Hassanin SO; Gowifel AMH; Hassan MSA
Arch Pharm (Weinheim); 2023 Dec; 356(12):e2300250. PubMed ID: 37792247
[TBL] [Abstract][Full Text] [Related]
27. Design and synthesis of some new 6-bromo-2-(pyridin-3-yl)-4-substituted quinazolines as multi tyrosine kinase inhibitors.
Farouk AKBAW; Abdelrasheed Allam H; Rashwan E; George RF; Abbas SE
Bioorg Chem; 2022 Nov; 128():106099. PubMed ID: 35994884
[TBL] [Abstract][Full Text] [Related]
28. Novel VEGFR-2 inhibitors as antiangiogenic and apoptotic agents via paracrine and autocrine cascades: Design, synthesis, and biological evaluation.
Abdel Rahman DE; Fouad MA; Mohammed ER; El-Zoheiry HH; Abdelrasheed Allam H
Bioorg Chem; 2023 Oct; 139():106678. PubMed ID: 37354661
[TBL] [Abstract][Full Text] [Related]
29. Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation.
Elwan A; Abdallah AE; Mahdy HA; Dahab MA; Taghour MS; Elkaeed EB; Mehany ABM; Nabeeh A; Adel M; Alsfouk AA; Elkady H; Eissa IH
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956997
[TBL] [Abstract][Full Text] [Related]
30. Molecular Design and Synthesis of New 3,4-Dihydropyrimidin-2(1H)-Ones as Potential Anticancer Agents with VEGFR-2 Inhibiting Activity.
Mostafa AS; Bayoumi WA; El-Mesery M; Elgaml A
Anticancer Agents Med Chem; 2019; 19(3):310-322. PubMed ID: 30019649
[TBL] [Abstract][Full Text] [Related]
31. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.
Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI
Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, and anti-proliferative evaluation of new quinazolin-4(3H)-ones as potential VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Ayyad RR; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Eissa IH
Bioorg Med Chem; 2021 Jan; 29():115872. PubMed ID: 33214036
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer.
Abdel-Mohsen HT; Abd El-Meguid EA; El Kerdawy AM; Mahmoud AEE; Ali MM
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900340. PubMed ID: 32045054
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel ureido benzothiophenes as dual VEGFR-2/EGFR anticancer agents.
Eldehna WM; Al-Ansary GH; Al-Warhi T; Jaballah MY; Elaasser M; Rashed M
Bioorg Chem; 2024 Feb; 143():107037. PubMed ID: 38134521
[TBL] [Abstract][Full Text] [Related]
35. Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Bioorg Med Chem; 2014 Sep; 22(17):4735-44. PubMed ID: 25082515
[TBL] [Abstract][Full Text] [Related]
36. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies.
Parmar DR; Soni JY; Guduru R; Rayani RH; Kusurkar RV; Vala AG; Talukdar SN; Eissa IH; Metwaly AM; Khalil A; Zunjar V; Battula S
Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975
[TBL] [Abstract][Full Text] [Related]
37. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
[TBL] [Abstract][Full Text] [Related]
38. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH
Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
[TBL] [Abstract][Full Text] [Related]
39. Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2.
Yousef RG; Eldehna WM; Elwan A; Abdelaziz AS; Mehany ABM; Gobaara IMM; Alsfouk BA; Elkaeed EB; Metwaly AM; Eissa IH
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807326
[TBL] [Abstract][Full Text] [Related]
40. Design and synthesis of novel hexahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives as potential anticancer agents with antiangiogenic activity via VEGFR-2 inhibition, and down-regulation of PI3K/AKT/mTOR signaling pathway.
Seif SE; Mahmoud Z; Wardakhan WW; Abdou AM; Hassan RA
Drug Dev Res; 2023 Aug; 84(5):839-860. PubMed ID: 37016480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]